FSMEX — Select Medical Technology and Devices Portfolio
Data updated: 2026-07-24
FSMEX — Select Medical Technology and Devices Portfolio data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Information Technology Equity · $2.98B AUM · 0.62% expense ratio · -10.2% 1-yr return. From SEC regulatory filings.
FSMEX Fund Overview
FSMEX — Select Medical Technology and Devices Portfolio is a US mutual fund managed by Fidelity Select Portfolios, categorised as United States Information Technology Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Fidelity Select Portfolios
- Category: United States Information Technology Equity
- Assets under management: $2.98B
- 1-year return: -10.2%
- Ticker: FSMEX
- SEC CIK: 0000320351
- SEC series ID: S000007473
- Share class ID: C000020447
FSMEX Holdings
Top 10 holdings of Select Medical Technology and Devices Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Danaher Corp. | 15.09% |
| Thermo Fisher Scientific, Inc. | 14.06% |
| Intuitive Surgical, Inc. | 7.45% |
| Boston Scientific Corp. | 5.11% |
| Edwards Lifesciences Corp. | 4.21% |
| Stryker Corp. | 4.18% |
| Abbott Laboratories | 3.85% |
| Waters Corp. | 3.27% |
| Agilent Technologies, Inc. | 3.21% |
| West Pharmaceutical Svcs, Inc. | 3.09% |
FSMEX Portfolio Allocation
Asset-class allocation of Select Medical Technology and Devices Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.3% |
| Cash & Equivalents | 3.4% |
| Fixed Income | 0.2% |
FSMEX Performance
Total returns for FSMEX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -15.8% |
| 1 year | -10.2% |
| 3 years (annualised) | -1.2% |
| 5 years (annualised) | -3.2% |
FSMEX Risk Information
Risk metrics for FSMEX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 15.1%
FSMEX Costs and Fees
FSMEX costs about $62 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.62%
- Gross expense ratio: 0.62%
- Portfolio turnover: 54%
- Brokerage commissions: 2.20 bps of average net assets (SEC N-CEN)
FSMEX Cashflows
Over the 12 months to 2026-02, Select Medical Technology and Devices Portfolio had net outflows of $729.75M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | −$83.67M |
| 2026-01 | −$91.36M |
| 2025-12 | $93.72M |
| 2025-11 | −$60.74M |
| 2025-10 | −$89.29M |
| 2025-09 | −$97.90M |
FSMEX Debt Constituents
Largest debt holdings of Select Medical Technology and Devices Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Galvanize Therapeutics | 0.22% |
FSMEX Prospectus and SEC Filings
Official Select Medical Technology and Devices Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Information Technology Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.